Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Visual Fields

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Visual Fields. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005601-22 Sponsor Protocol Number: poc1doxy Start Date*: 2008-03-27
    Sponsor Name:
    Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ...
    Medical condition: Diabetic retinopathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012689 Diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000658-30 Sponsor Protocol Number: prot PDR 1 Start Date*: 2007-03-02
    Sponsor Name:Royal Victoria Eye and Ear hospital
    Full Title: Randomised controlled trial of Intravitreal Bevacizumab vs. conventional treatment for proliferative diabetic retinopathy.
    Medical condition: Proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005113-39 Sponsor Protocol Number: SSP-2 Start Date*: 2013-04-08
    Sponsor Name:Universitätsklinik für Neurologie, Medizinische Universität Wien
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis
    Medical condition: Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003272-12 Sponsor Protocol Number: SIVS1012 Start Date*: 2014-04-08
    Sponsor Name:Moorfields Eye Hospital
    Full Title: Clinical Efficacy and Mechanistic Evaluation of Aflibercept for Proliferative Diabetic Retinopathy
    Medical condition: Proliferative Diabetic Retinopathy (PDR)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002531-15 Sponsor Protocol Number: 09/0959 Start Date*: 2016-11-14
    Sponsor Name:UCL Comprehensive Clinical Trials Unit
    Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis
    Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10047560 Visual field perimetric tests LLT
    19.0 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    19.0 100000004867 10021948 Infiltration intravenous injection LLT
    19.0 10022891 - Investigations 10057208 Optical coherence tomography PT
    19.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    19.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    19.0 10022891 - Investigations 10047566 Visual field tests PT
    19.0 10015919 - Eye disorders 10009034 Chronic open angle glaucoma LLT
    19.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    19.0 10015919 - Eye disorders 10006027 Borderline glaucoma PT
    19.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    19.0 10015919 - Eye disorders 10006028 Borderline glaucoma (glaucoma suspect) LLT
    19.0 10029205 - Nervous system disorders 10004571 Bilateral optic neuritis LLT
    19.0 10029205 - Nervous system disorders 10012121 Defect visual field (NOS) LLT
    19.0 100000004865 10020422 HRT LLT
    19.0 10015919 - Eye disorders 10018304 Glaucoma PT
    19.0 100000004865 10048541 Intravenous catheter management LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002249-11 Sponsor Protocol Number: BLQ-01-003-04 Start Date*: 2004-09-20
    Sponsor Name:BAUSCH&LOMB - IOM S.P.A.
    Full Title: Double blind, randomized, multicenter, placebo-controlled, parallel-group design clinical trial of the efficacy and tolerability of cloriclomene hydrochloride capsules 100 mg TID in diabetic patien...
    Medical condition: Mild to moderate non-proliferative diabetic retinopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001200-38 Sponsor Protocol Number: 4C-2011-02 Start Date*: 2012-09-07
    Sponsor Name:BCN Peptides S.A.
    Full Title: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomized controlled trial to assess the efficacy of neuroprotective dru...
    Medical condition: Prevention of neurodegeneration which occurs in Diabetic Retinopathy
    Disease: Version SOC Term Classification Code Term Level
    15.1 10015919 - Eye disorders 10012689 Diabetic retinopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003079-31 Sponsor Protocol Number: QRK207 Start Date*: 2016-10-20
    Sponsor Name:Quark Pharmaceuticals Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU...
    Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10068242 Nonarteritic anterior ischaemic optic neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001266-26 Sponsor Protocol Number: GS-LHON-CLIN-03B Start Date*: 2016-01-21
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 months a...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001265-11 Sponsor Protocol Number: GS-LHON-CLIN-03A Start Date*: 2016-01-21
    Sponsor Name:GENSIGHT-BIOLOGICS
    Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by...
    Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016760-36 Sponsor Protocol Number: CC-02-2009 Start Date*: 2010-02-05
    Sponsor Name:AIBILI
    Full Title: Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy)...
    Medical condition: Proliferative Diabetic Retinopathy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036857 Proliferative diabetic retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004980-39 Sponsor Protocol Number: Amiloride02 Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: A double blind randomised controlled trial on neuroprotection of amiloride in optic neuritis
    Medical condition: Optic Neuritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-011157-41 Sponsor Protocol Number: LT2345-PIII-12/08 Start Date*: 2009-07-24
    Sponsor Name:laboratoires théa
    Full Title: Efficacy and Safety assessment of T2345 unpreserved eyedrops versus Xalatan® in ocular hypertensive or glaucomatous patients. Phase III study, multicentre, international, randomised, investigator-m...
    Medical condition: The study population is suffering from glaucoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018304 Glaucoma LLT
    9.1 10018304 Glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002957-42 Sponsor Protocol Number: EMR200592-001 Start Date*: 2013-08-06
    Sponsor Name:Merck KGaA
    Full Title: A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjec...
    Medical condition: Locally advanced unresectable pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) SK (Completed) IT (Completed) PL (Completed) FI (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014269-25 Sponsor Protocol Number: A0081096 Start Date*: 2009-12-18
    Sponsor Name:Pfizer Inc
    Full Title: PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO
    Medical condition: EPILEPSY WITH PARTIAL SEIZURE
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10065336 Partial epilepsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-000155-34 Sponsor Protocol Number: 2 79 52030 207 Start Date*: 2008-06-02
    Sponsor Name:Beaufour Ipsen Pharma
    Full Title: PHASE IIIb, MULTICENTRE, OPEN-LABEL, SINGLE-ARM, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LANREOTIDE AUTOGEL 120 mg ADMINISTERED EVERY 28 DAYS AS PRIMARY MEDICAL TREATMENT IN ACROMEGALIC PATIENTS...
    Medical condition: ACROMEGALY ASSOCIATED WITH PITUITARY GLAND MACROADENOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) ES (Prematurely Ended) SE (Completed) GB (Completed) BE (Completed) CZ (Completed) FI (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004783-35 Sponsor Protocol Number: OPH2005 Start Date*: 2018-07-10
    Sponsor Name:IVERIC bio
    Full Title: A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease
    Medical condition: Autosomal Recessive Stargardt Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10062766 Stargardt's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) GB (GB - no longer in EU/EEA) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006075-42 Sponsor Protocol Number: ALXN1210-NMO-317 Start Date*: 2022-05-17
    Sponsor Name:Alexion Pharmaceuticals, Inc.
    Full Title: A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents Wit...
    Medical condition: Neuromyelitis Optica Spectrum Disorder (NMOSD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10077875 Neuromyelitis optica spectrum disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002574-52 Sponsor Protocol Number: 1698-301-007 Start Date*: 2019-08-01
    Sponsor Name:Allergan Ltd.
    Full Title: A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension
    Medical condition: Open-Angle Glaucoma or Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030856 Open-angle glaucoma LLT
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) SE (Completed) CZ (Trial now transitioned) HU (Ongoing) PL (Trial now transitioned) DK (Trial now transitioned) BG (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004262-95 Sponsor Protocol Number: 0130A01SA Start Date*: 2019-01-07
    Sponsor Name:Santen SAS
    Full Title: Phase III, Multinational, Multicenter, Investigator-Masked, Randomised, Active-Controlled Trial, comparing the efficacy and safety of DE-130A with Xalatan® in Patients with Open-Angle Glaucoma or O...
    Medical condition: Open-Angle Glaucoma or Ocular Hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    20.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) DE (Completed) EE (Completed) PL (Completed) ES (Completed) BE (Completed) AT (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA